- On Wednesday, April 1, 2026, the U.S. Food and Drug Administration approved Eli Lilly and Company's Foundayo , a once-daily oral GLP-1 pill for chronic weight management in adults with obesity or weight-related medical problems.
- The agency granted this approval in 50 days under its National Priority Voucher program, the fastest new molecular entity clearance since 2002, following Lilly's 2018 licensing of the molecule from Japan's Chugai Pharmaceutical Co., Ltd.
- Clinical trial data from the ATTAIN-1 program showed participants on the highest dose lost an average of 12.4% of body weight over 72 weeks; the pill offers flexibility as it lacks food or water restrictions.
- Lilly will begin direct shipments via its LillyDirect platform on April 6, with pricing starting at $149 for self-pay patients; eligible Medicare Part D beneficiaries may access the pill for $50 beginning July 1.